AXDX Earnings Prediction
The chart below shows how AXDX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AXDX sees a +3.54% change in stock price 10 days leading up to the earnings, and a -3.48% change 10 days following the report. On the earnings day itself, the stock moves by -0.61%. This data can give you a slight idea of what to expect for the next quarter's release.
AXDX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.98M
-9.82%
-0.37%
Gross Margin
28.77%
-26.48%
27.08%
Operating Margin
-289.68%
-29.03%
0.51%
Net Margin
-492.07%
-1884.16%
26.80%
EPS
-0.59
-1083.33%
18.00%
No Data Available
AXDX Earnings Analysis
Accelerate Diagnostics, Inc. Corporation (AXDX.O) Earnings Conference Call
Positive
Clinical Trial Progress Update: Our clinical trial for the WAVE system and Gram-Negative testing menu is on track with external site enrollments meeting our expectations.
Clinical Performance Evaluation: The trial's clinical performance at all four external laboratories meets our expectations thus far.
FDA Submission Timeline: We anticipate submitting to the FDA in Q1 of 2025 with a review timeline of approximately nine months.
FDA Clearance Achieved: We obtained FDA 510(k) clearance for our Accelerate Arc system, including the blood culture kit.
Gross Margin Improvement: Our gross margin was approximately 29% for the quarter, which compares to approximately 3% in the same period in the prior year.
Negative
Quarterly Net Sales Comparison: Net sales were approximately $3 million for the quarter, which compares to approximately $3.3 million for the same period in the prior year.
Net Sales Decline: We did see a decrease in overall net sales period-over-period which was driven by lower instrument sales in the current quarter.
Gross Margin Improvement: Gross margin was approximately 29% for the quarter which compares to approximately 3% in the same period in the prior year.
SG&A Expense Reduction: Selling, general and administrative expenses were approximately $5.6 million for the quarter which compares to $7.8 million in the same period in the prior year.
R&D Expense Comparison: Research and development expenses were $3.8 million for the quarter which compares to $7 million for the same period in the prior year.
AXDX FAQs
How does AXDX typically perform around its earnings report dates?
Is Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AXDX Earning Call Sentiment
Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AXDX.O
-3.49%Positive
The earnings call presents mixed signals. While the company shows progress in gross margin improvement and cost reduction, net sales have decreased, and net loss has widened. The Q&A highlights optimism around product launches and customer conversion but lacks concrete guidance. Regulatory and competitive risks also pose challenges. Without market cap data, a neutral prediction is prudent, as positive developments are balanced by ongoing financial and operational uncertainties.
